Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor.

By A. Haes, Lei Chang, W. Klein, R. V. Van Duyne. Journal of the American Chemical Society, 2005

802 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease (2007, background): “The premise that ADDLs occur extracellularly was verified recently in nanotechnology-based assays (Georganopoulou et al., 2005; Haes et al., 2005), which established diseasedependent accumulation of ADDLs in CSF.”
Localized Surface Plasmon Resonance Biosensing: Current Challenges and Approaches (2015, background): “in 2005 and detected a biomarker, amyloid-derived diffusible ligand (ADDL), for Alzheimer’s disease [131].”
Nanobiosensors based on localized surface plasmon resonance for biomarker detection (2012, methodology): “[15] developed an LSPR biosensor capable of biomarker detection for Alzheimer’s disease, that is, detection of amyloid-derived diffusible ligands (ADDLs), at picomolar concentrations (Figure 7(a)).”